Date: 2016-07-14
Type of information: Publication of results in a medical journal
phase:
Announcement: publication of results in Vaccine
Company: Curevac (Germany)
Product: RNActive® technology
Action
mechanism: vaccine/mRNA.
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On July 14, 2016, CureVac announced that a study of its RNActive® technology was published in Vaccine. The study, titled, “Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity,” demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines. The study evaluated the early events upon intradermal application of RNActive® to gain a more detailed understanding of the underlying mode of action of the mRNA vaccine. RNActive is a two-component, self-adjuvanted vaccine that combines high antigen expression with potent adjuvant capacity, which induces balanced immune responses. Mariola Fotin-Mleczek, Ph.D., CSO of CureVac, stated, “The results of this study are very exciting, since this is the first time the mode of action of an mRNA vaccine was described in great detail. In this respect, local administration seems to be a very effective approach for inducing a strong systemic immune response. At the same time this approach exhibits a beneficial safety profile, as activation of the innate immune system is transient and limited to the application site and draining lymph nodes, yet generates boostable systemic immunity. By characterizing the early events following mRNA application, we now have not only a proven mechanistic rationale for the observed efficacy of mRNA vaccines, but an excellent basis and accelerator for our ongoing development of potent and safe mRNA products.”
